Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 5, 1997, Pages 435-440

  Komaki, Ritsuko ^a   Scott, Charles ^b   Lee, Jin S ^a   Urtasun, Raul C ^c   Byhardt, Roger W ^d   Emami, Bahman ^e   Andras, Ellis J ^f   Asbell, Sucho O ^a   Rotman, Marvin ^d   Cox, James D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Medical College of Wisconsin   (United States)

^d Radiological Associates of Sacramento Medical Group Inc   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Hyperfractionation; Lung Cancer; Non small cell lung cancer; Radiation therapy; Radiation Therapy Oncology Group

Indexed keywords

CISPLATIN; ETOPOSIDE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY SURFACE AREA; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CISPLATIN; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; RADIOTHERAPY; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE; WEIGHT LOSS;

EID: 0030754853     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199710000-00002     Document Type: Article

References (17)

1. Cancer facts & Figures-1996. Atlanta, GA: American Cancer Society, 1996.
2. Ferez ÇA, Stanley K, Rubin P, et al. A prospective randomized study of the various radiation doses and fractionation schedules and the treatment of inoperable non-oat cell carcinoma of the lung: preliminary report by Radiation Therapy Oncology Group. Cancer 1980;45:2744-53.
3. Cox JD, Azarnia N, Byhardt RV, Shin KH, Emami B., Pajak T. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses 60.0 to 79.2 Gy; possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III nonsmall cell lung carcinoma; report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-55.
4. Dillman RO, Seagren SL, Proper! KJ, et ai. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III nonsmall cell lung cancer. N Engl J Med 1990;323:940-5.
5. Byhardt RW, Scott CB, Ettinger DS, et al. Concurrent hyperfrac-tionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer 1995;75:2337-44.
6. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral VP-16 and cisplatin for locally advanced inoperable nonsmall cell lung cancer: RTOG Protocol 91-06. J Clin Oncol 1996; 14:1055-64.
7. Diener-West M, Pajak TF, Bauer M, Cox JD. Randomized dose searching phase ILE/II trials of fractionation in radiation therapy for cancer. J Natl Cancer lust 1991;83:1065-71.
8. Winchester DP, Cox JD. Standards for breast-conservation treatment. CA Cancer J Clin 1992;42:134-62.
9. Mehta C, Patel N. StatXact. Cambridge, MA: CYTEL Software, 1992.
10. Kaplan EL, Meier P. Nonparametric estimation from the incomplete observations. J Am Slat Assoc 1958;54:457-81.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
12. Caplan RJ, Pajak TF, Cox JD. Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Pliys 1994;29:1183-6.
13. Gray RJ. A class of K-sampIe tests for comparing the cumulative incidence of a competing risk. Ann Slat 1988; 16:1141-54.
14. Dixon WJ. BMDP statistical software manual. Berkeley, CA: University of California Press, 1992.
15. Komaki R, Scott C, Ettinger D, et al. Randomized phase II study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell cancer: Radiation Therapy Oncology Group 92-04 [Abstract 1656]. Proc Am Soc Clin Oncol 1996; 15:514.
16. Reboul F, Chauvet B, Vincent P, Brewer Y, Felix-Faure C, Taullelle M. Endobronchial high-dose rate brachytherapy: local efficacy and complications in 111 patients [Abstract]. Lung Cancer 1994;II:134.
17. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer lust 1995;87:198-205.